To examine the use of low-dose ritonavir as a pharmacokinetic enhancer for HIV protease inhibitors.
DATA SOURCES:
Primary articles, review articles, and conference abstracts identified by MEDLINE search (1995–May 2001) and secondary sources.
DATA SYNTHESIS:
Low-dose ritonavir (100–200 mg) is increasingly being combined with HIV protease inhibitors to improve their effectiveness and allow less frequent dosing. An evaluation of the clinical evidence supporting this practice was conducted.
CONCLUSIONS:
Limited outcome data exist for low-dose ritonavir-based regimens in general. Although preliminary data appear promising, more clinical evidence is needed to determine the optimal dosing, long-term safety, and relative effectiveness of this approach. The role of these regimens in early therapy remains to be defined.
Product information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, March 2000.
2.
CameronDWHeath-ChiozziMDannerSCohenCKravcikSMaurathC. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet1998; 351: 543–9.
3.
RubleinJCEronJJJr.ButtsJDRaaschRH. Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg. Ann Pharmacother1999; 33: 899–905.
4.
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation [accessed 2001 Aug 13]. Available from: URL: http://www.hivatis.org.
5.
FlexnerC. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefit. Annu Rev Pharmacol Toxicol2000; 40: 649–74.
6.
van HeeswijkRPGVeldkampAIHoetelmansRMWMulderJWSchreijGHsuA. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS1999; 13: F95–9.
7.
BurgerDMHugenPWHAarnoutseREDielemanJPPrinsJMvan der PollT. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: Pharmacokinetics, safety, efficacy. J Acquir Immune Defic Syndr2001; 26: 218–24.
8.
GatellJMLangeJArnaizJAFaetkenheuerGMallolasJClotetB. A randomized study comparing continued indinavir (800 mg tid) versus switching to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleoside analogues: The BID Efficacy and Safety Trial (BEST) (abstract). Presented at the XIII International AIDS Conference, Durban, South Africa, July 9–14, 2000: WeOrB484.
9.
BoydMDuncombeCNewellMUngsedhapandCRuxrungthamKKhongphattanayothinM. Indinavir/ritonavir vs. indinavir in combination with AZT/3TC for treatment of HIV in nucleoside-experienced patients: a randomized, open-label trial (abstract). Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001: 335.
10.
GrossmanHPurdomDButcherDFrechetteGChamlaisPGlazerE. Experience of indinavir (IDV) plus ritonavir (RTV) as part of a salvage regimen in extensively pretreated HIV patients in clinical practice (abstract). Presented at the XIII International AIDS Conference, Durban, South Africa, July 9–14, 2000: WePeB4183.
11.
CasadoJLMorenoAMarti-BeldaPSabidoRGarcia-ArataIPerez-EliasMJ. Increased indinavir levels using twice daily ritonavir/indinavir at 100/800 mg improves virologic response even after multiple failure (abstract). Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000: 1170.
12.
EstradaVDeGorgolasMRocaVDeVillarNTellezMJ. Tolerance and efficacy of indinavir 800 mg plus ritonavir 100 mg bid in addition to nucleoside analogues in HIV infected patients (abstract). Presented at the XIII International AIDS Conference, Durban, South Africa, July 9–14, 2000: TuPeB3232.
13.
CampoRESuarezGAMillerNMorenoJKolberMHolderDJ. Efficacy of indinavir (IDV)/ritonavir(RTV)–based regimens (IRBR) among patients with prior protease inhibitor failure (abstract 7). Antivir Ther2000; 5 (suppl 2):6.
14.
CondraJHPetropoulosCJZiermannRSchleifWAShivaprakashMEminiEA. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis2000; 182: 758–65.
15.
MallolasJBlancoJLSarasaMGinerVMartinezEGarcia-ViejoMA. Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients. J Acquir Immune Defic Syndr2000; 25: 229–35.
16.
HugenPWBurgerDMTer HofstedeHJKoopmansPPStekMHeksterYA. Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr2000; 25: 236–45.
17.
SuleimanJRhodesRCampoRPilieroPSteigbigelRChenJ. Preliminary results from indinavir (IDV) and ritonavir (RTV) in a once-daily regimen (Merck 103/104) (abstract). Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001: 336.
18.
KilbyMHillAMBussN. The effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of 120 subjects (abstract). Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000: 1650.
19.
KilbyJMSfakianosGGizziNSiemon-HryczykPEhrensingEOoC. Safety and pharmacokinetics of once-daily regimens of soft-gel saquinavir plus minidose ritonavir in human immunodeficiency virusnegative adults. Antimicrob Agents Chemother2000; 44: 2672–8.
20.
van HeeswijkRPGVeldkampAIMulderJWMeenhorstPLLangeJMABeijnenJH. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: A pharmacokinetic pilot study. AIDS2000; 14: F103–110.
21.
SadlerBMPilieroPJPrestonSLLloydPPLouYSteinDS. Pharmacokinetics and safety of amprenavir and ritonavir following multipledose, co-administration to healthy volunteers. AIDS2001; 15: 1009–18.
22.
Anne-MarieTBonaventure-PaciSGoujardCVoncentIRousseauCCheminotN. Therapeutic drug monitoring of amprenavir combined with ritonavir as salvage therapy in HIV-1 infected patients (abstract). Presented at the XIII International AIDS Conference, Durban, South Africa, July 9–14, 2000: TuPeB3305.
23.
HsuRBellmanPC. The combination of ritonavir and amprenavir in salvage regimens overcomes clinically multiple-drug resistant HIV (abstract). Presented at the XIII International AIDS Conference, Durban, South Africa, July 9–14, 2000: WePeB4204.
24.
Product information. Agenerase (amprenavir). Research Triangle Park, NC: GlaxoSmithKline, February 2002.
25.
WoodRTrepoCLivrozetLMArastehKEronJKaiuP. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naïve HIV-1-infected adults over 12 weeks (AV20001) (abstract). Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001: 332.
26.
KurowskiMKaeserBMroziekiewiczAArslanAPopescuM. The influence of ritonavir on the pharmacokinetics of nelfinavir 1250 mg BID (abstract). Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000: 1639.
27.
HsyuPHLewisRTranJLillibridgeJSchultz-SmithMKerrB. Pharmacokinetics (PK) of nelfinavir (NFV) after once daily dosing in combination with mini-doses of ritonavir (RTV) in healthy subjects (abstract). Presented at the XIII International AIDS conference, Durban, South Africa, July 9–14, 2000: LbPeB7049.
28.
PiscitelliSCGallicanoKD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med2001; 344: 984–96.
29.
MurphyRLBrunSHicksCEronJJGulickRKingM. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. AIDS2001; 15: F1–9.
30.
BensonCBrunSKingMRealKMurphyRHicksC. Two year follow-up of ABT-378/ritonavir (ABT-378/r) in antiretroviral naïve HIV+ patients. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000: 546.
31.
WalmsleySBadleyABeallGCameronWJohnsonDJohnsonM. Efficacy of ABT-378 vs. nelfinavir (NFV) in antiretroviral (ARV)-naïve subjects: results of a Phase III blinded randomized clinical trial. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000: 693.
